## Abstract ## Objective Rheumatoid arthritis (RA) is considered to be a prototypical autoimmune disease. However, the autoantigens that play an important role in the development of RA remain unclear. The aim of this study was to investigate whether T cells specific for citrullinated epitopes from
Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study
✍ Scribed by F. A. van Gaalen; S. P. Linn-Rasker; W. J. van Venrooij; B. A. de Jong; F. C. Breedveld; C. L. Verweij; R. E. M. Toes; T. W. J. Huizinga
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 70 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Objective
Rheumatoid arthritis (RA) is a common, severe, chronic inflammatory joint disease. Since the disease may initially be indistinguishable from other forms of arthritis, early diagnosis can be difficult. Autoantibodies seen in RA can be detected years before clinical symptoms develop. In an inception cohort of patients with recent‐onset arthritis, we undertook this study to assess the predictive value of RA‐specific autoantibodies to cyclic citrullinated peptides (CCPs) in patients with undifferentiated arthritis (UA).
Methods
Anti‐CCP2 antibody tests were performed at baseline in 936 consecutive, newly referred patients with recent‐onset arthritis. Patients who could not be properly classified 2 weeks after inclusion were categorized as having UA. Patients with UA were followed up for 3 years and evaluated for progression of their disease to RA as defined by the American College of Rheumatology (ACR) 1987 revised criteria.
Results
Three hundred eighteen of 936 patients with recent‐onset arthritis were classified as having UA and were available for analysis. After 3 years of followup, 127 of 318 UA patients (40%) had been classified as having RA. RA had developed in 63 of 249 patients (25%) with a negative anti‐CCP test and in 64 of 69 patients (93%) with a positive anti‐CCP test (odds ratio 37.8 [95% confidence interval 13.8–111.9]). Multivariate analysis of the presence of anti‐CCP antibodies and parameters from the ACR criteria identified polyarthritis, symmetric arthritis, erosions on radiographs, and anti‐CCP antibodies as significant predictors of RA.
Conclusion
Testing for anti‐CCP antibodies in UA allows accurate prediction of a substantial number of patients who will fulfill the ACR criteria for RA.
📜 SIMILAR VOLUMES
## Abstract ## Objective Patients with rheumatoid arthritis (RA) who experience treatment failure with one anti–tumor necrosis factor (anti‐TNF) agent, due to either inefficacy or toxicity, are frequently switched to a second anti‐TNF agent, although the benefits of switching are unknown. The pres